Literature DB >> 34505533

The assessment of plasma fatty acid profiles in newly diagnosed treatment-naive paediatric Crohn's disease.

J Schwarz1, M Vecka, F Stožický, R Pomahačová, B Staňková, E Tvrzická, M Kreslová, R Zahálková, J Sýkora.   

Abstract

Fatty acid (FA) profiles as potentially relevant components of Crohn's disease (CD) have been insufficiently analysed. We sought to explore the plasma profiles of n-3 and n-6 polyunsa-turated fatty acids (PUFAs) in newly diagnosed untreated active CD. We included 26 consecutive CD pediatric patients (<19 years) and 14 healthy controls (HCs). Disease characteristics, including inflammatory markers, dietary histories, and the Pediatric Crohn's Disease Activity Index (PCDAI), were obtained. The profiles of plasma FAs in plasma lipid classes were analysed by gas chromatography with FID detection of methyl esters. The erythrocyte sedimentation rate, C-reactive protein level and fecal calprotectin level (all p<0.001) were significantly higher in CD patients than in HCs. Most changes were observed in plasma phospholipids (PLs), such as a higher content of n-3 and changes in n-6 long-chain PUFAs in the CD group. The CD group had a lower ratio of n-6/n-3 PUFAs in PLs (p<0.001) and triacylglycerols (TAGs) (p<0.01). Correlations of the FA content in plasma PLs with disease activity scores of CD were also observed, which were positive for the sum of monounsaturated fatty acids (MUFAs) as well as oleic acid (18:1n-9) (both p<0.05). The metabolism of PUFAs is significantly altered even in treatment-naive newly diagnosed active pediatric CD, and the content of major FAs in PLs correlates with disease activity and inflammatory markers, thus probably contributing to the still unclear early disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34505533      PMCID: PMC8820526          DOI: 10.33549/physiolres.934665

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  38 in total

1.  Abnormal fatty acid pattern in intestinal mucosa of children with celiac disease is not reflected in serum phospholipids.

Authors:  Daniella M Steel; Walter Ryd; Henry Ascher; Birgitta Strandvik
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-09       Impact factor: 2.839

2.  Effect of gamma-linolenic acid or docosahexaenoic acid on tight junction permeability in intestinal monolayer cells and their mechanism by protein kinase C activation and/or eicosanoid formation.

Authors:  Makoto Usami; Takako Komurasaki; Aki Hanada; Kaori Kinoshita; Atsushi Ohata
Journal:  Nutrition       Date:  2003-02       Impact factor: 4.008

3.  Essential fatty acid depletion in children with inflammatory bowel disease.

Authors:  Piotr Socha; Józef Ryzko; Berthold Koletzko; Danuta Celinska-Cedro; Marek Woynarowski; Piotr Czubkowski; Jerzy Socha
Journal:  Scand J Gastroenterol       Date:  2005-05       Impact factor: 2.423

Review 4.  Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators.

Authors:  C N Serhan
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 5.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

Review 6.  Omega-6 fatty acids and inflammation.

Authors:  Jacqueline K Innes; Philip C Calder
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-03-22       Impact factor: 4.006

7.  Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease.

Authors:  M Esteve-Comas; M Ramírez; F Fernández-Bañares; A Abad-Lacruz; A Gil; E Cabré; F González-Huix; J Moreno; P Humbert; M Guilera
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

8.  Serum Polyunsaturated Fatty Acids Correlate with Serum Cytokines and Clinical Disease Activity in Crohn's Disease.

Authors:  Elizabeth A Scoville; Margaret M Allaman; Dawn W Adams; Amy K Motley; Shannon C Peyton; Sarah L Ferguson; Sara N Horst; Christopher S Williams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

Review 9.  Omega Fatty Acids and Inflammatory Bowel Diseases: An Overview.

Authors:  Ledyane Taynara Marton; Ricardo de Alvares Goulart; Antonelly Cassio Alves de Carvalho; Sandra Maria Barbalho
Journal:  Int J Mol Sci       Date:  2019-09-30       Impact factor: 5.923

10.  ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents.

Authors:  Arie Levine; Sibylle Koletzko; Dan Turner; Johanna C Escher; Salvatore Cucchiara; Lissy de Ridder; Kaija-Leena Kolho; Gabor Veres; Richard K Russell; Anders Paerregaard; Stephan Buderus; Mary-Louise C Greer; Jorge A Dias; Gigi Veereman-Wauters; Paolo Lionetti; Malgorzata Sladek; Javier Martin de Carpi; Annamaria Staiano; Frank M Ruemmele; David C Wilson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-06       Impact factor: 3.288

View more
  1 in total

1.  Circulating levels of WISP-1 (Wnt1-inducible signaling pathway protein 1) and other selected adipokines in children with inflammatory bowel disease.

Authors:  E Karásková; V Kubickova; M Velganova-Veghova; M Geryk; H Foltenova; D Karasek
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.